Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

"Eli Lilly's Growth: What It Means for Your Health"

Eli Lilly and Company recently reported impressive financial results for the second quarter of 2026, showcasing a 48% revenue increase to $23 billion, largely driven by the strong performance of its weight-loss medications, Mounjaro and Zepbound. The company also raised its full-year revenue guidance, anticipating between $85 billion and $87 billion, while earnings per share (EPS) rose by 26% to $7.94. This growth reflects not only successful product sales but also strategic business development, including several acquisitions aimed at enhancing their therapeutic offerings.

For individuals interested in healthy aging, the advancements from Lilly could have significant implications. The company’s focus on obesity treatment through drugs like Mounjaro may offer new avenues for managing weight, which is crucial for reducing the risk of chronic diseases such as diabetes and heart disease. With a 91% increase in Mounjaro’s revenue, it’s clear that demand for effective weight management solutions is on the rise, potentially benefiting many who struggle with obesity and related health issues.

The reported results stem from a combination of strong sales and strategic investments, including the completion of multiple acquisitions to bolster their pipeline. While these results are promising, they come from a large corporate report rather than clinical trials, meaning that while the financial growth indicates strong market performance, the direct benefits of new medications for individual health are still in development stages. Lilly’s commitment to expanding its manufacturing capabilities and advancing its research pipeline suggests a bright future for innovative treatments, but consumers should remain cautious as these products undergo regulatory approval processes.

As Lilly continues to innovate, staying informed about new medications and treatments can empower you to make better health decisions. If you are interested in weight management or other health improvements, consider discussing these new options with your healthcare provider.